CAR T-cell cancer therapies: do not forget the heart
- PMID: 36994886
- DOI: 10.1093/eurheartj/ehad175
CAR T-cell cancer therapies: do not forget the heart
Conflict of interest statement
Conflict of interest M.T. reports speaker fees and personal support from Bayer, Daiichi Sankyo, BMS, Pfizer, Berlin Chemie, Novartis, and Edwards, outside the submitted work. M.S.A. reports personal fees from Servier, outside the submitted work. T.R. reports speaker fees and personal support from Bayer, Daiichi Sankyo, BMS, Pfizer, Berlin Chemie, Novartis, and Edwards, outside the submitted work.
Comment on
-
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.Eur Heart J. 2023 Jun 9;44(22):2029-2042. doi: 10.1093/eurheartj/ehad117. Eur Heart J. 2023. PMID: 36939851 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical